Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014736621> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2014736621 endingPage "1145" @default.
- W2014736621 startingPage "1142" @default.
- W2014736621 abstract "To represent industry on the topic of this conference, position papers were obtained from six pharmaceutical and biotechnology companies. Despite their holding a wide range of positions in the market with regard to prevention and treatment of osteoporosis, all companies were unanimous in their concerns about the ability to conduct randomized placebo-controlled clinical trials (PCTs) in the future. The clinical research environment contains conflicting directives. Regulatory agencies strongly prefer (even insist on) PCTs as a requirement for drug approval, while many physicians, human studies institutional review boards, and informed patients believe that it is no longer ethical to place osteoporotic patients on placebo because effective therapies are now available. PCTs offer the best means of calibrating the absolute efficacy of a new agent and identifying its side effects against a neutral background. Are comparison-controlled clinical trials (CCTs) using an approved drug the answer? No. Examples are given that illustrate that such trials require very large numbers of patients to show non-inferiority (approximately 15,000-20,000) or superiority (approximately 30,000) compared with an existing approved therapy. Such studies are not only impractical, but also accumulate a greater number of fractures during the course of clinical research in both the new treatment and control (active comparator) groups than would occur in PCTs. Total adverse experiences and exposure of patients to investigational agents is considerably greater when CCTs rather than PCTs are used. Based on this analysis, industry recommends that regulatory approval of new agents for osteoporosis be based on (1) conduct of PCTs in patients at low risk for fracture (e.g., T-score < -2.5 and no previous osteoporotic fracture); (2) use of bone mineral density as an end-point for the indication to preserve or improve bone mass; (3) a 2-year, rather than 3-year, trial period; (4) demonstration of no adverse effect on bone quality preclinically; (5) extrapolation of clinical trial results to higher risk patients; (6) an option for the sponsor to perform additional fracture end-point studies postapproval to obtain an indication for treatment to reduce the risk of fractures specifically in the spine, hip, or both; and (7) the option to file for a prevention claim before a treatment claim." @default.
- W2014736621 created "2016-06-24" @default.
- W2014736621 creator A5085901971 @default.
- W2014736621 date "2003-06-01" @default.
- W2014736621 modified "2023-10-15" @default.
- W2014736621 title "Is It Ethical to Conduct Placebo-Controlled Clinical Trials in the Development of New Agents for Osteoporosis? An Industry Perspective" @default.
- W2014736621 cites W1526826623 @default.
- W2014736621 cites W2005298224 @default.
- W2014736621 cites W2112629831 @default.
- W2014736621 cites W2335178464 @default.
- W2014736621 doi "https://doi.org/10.1359/jbmr.2003.18.6.1142" @default.
- W2014736621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12817772" @default.
- W2014736621 hasPublicationYear "2003" @default.
- W2014736621 type Work @default.
- W2014736621 sameAs 2014736621 @default.
- W2014736621 citedByCount "15" @default.
- W2014736621 countsByYear W20147366212012 @default.
- W2014736621 countsByYear W20147366212015 @default.
- W2014736621 crossrefType "journal-article" @default.
- W2014736621 hasAuthorship W2014736621A5085901971 @default.
- W2014736621 hasBestOaLocation W20147366211 @default.
- W2014736621 hasConcept C126322002 @default.
- W2014736621 hasConcept C12713177 @default.
- W2014736621 hasConcept C141071460 @default.
- W2014736621 hasConcept C142724271 @default.
- W2014736621 hasConcept C154945302 @default.
- W2014736621 hasConcept C168563851 @default.
- W2014736621 hasConcept C177713679 @default.
- W2014736621 hasConcept C1862650 @default.
- W2014736621 hasConcept C197934379 @default.
- W2014736621 hasConcept C204787440 @default.
- W2014736621 hasConcept C27081682 @default.
- W2014736621 hasConcept C41008148 @default.
- W2014736621 hasConcept C502991105 @default.
- W2014736621 hasConcept C512399662 @default.
- W2014736621 hasConcept C535046627 @default.
- W2014736621 hasConcept C71924100 @default.
- W2014736621 hasConcept C98274493 @default.
- W2014736621 hasConceptScore W2014736621C126322002 @default.
- W2014736621 hasConceptScore W2014736621C12713177 @default.
- W2014736621 hasConceptScore W2014736621C141071460 @default.
- W2014736621 hasConceptScore W2014736621C142724271 @default.
- W2014736621 hasConceptScore W2014736621C154945302 @default.
- W2014736621 hasConceptScore W2014736621C168563851 @default.
- W2014736621 hasConceptScore W2014736621C177713679 @default.
- W2014736621 hasConceptScore W2014736621C1862650 @default.
- W2014736621 hasConceptScore W2014736621C197934379 @default.
- W2014736621 hasConceptScore W2014736621C204787440 @default.
- W2014736621 hasConceptScore W2014736621C27081682 @default.
- W2014736621 hasConceptScore W2014736621C41008148 @default.
- W2014736621 hasConceptScore W2014736621C502991105 @default.
- W2014736621 hasConceptScore W2014736621C512399662 @default.
- W2014736621 hasConceptScore W2014736621C535046627 @default.
- W2014736621 hasConceptScore W2014736621C71924100 @default.
- W2014736621 hasConceptScore W2014736621C98274493 @default.
- W2014736621 hasIssue "6" @default.
- W2014736621 hasLocation W20147366211 @default.
- W2014736621 hasLocation W20147366212 @default.
- W2014736621 hasOpenAccess W2014736621 @default.
- W2014736621 hasPrimaryLocation W20147366211 @default.
- W2014736621 hasRelatedWork W2085830368 @default.
- W2014736621 hasRelatedWork W2115848393 @default.
- W2014736621 hasRelatedWork W2157531023 @default.
- W2014736621 hasRelatedWork W2332746628 @default.
- W2014736621 hasRelatedWork W2412528326 @default.
- W2014736621 hasRelatedWork W2461838604 @default.
- W2014736621 hasRelatedWork W2898992494 @default.
- W2014736621 hasRelatedWork W2923890311 @default.
- W2014736621 hasRelatedWork W3182450353 @default.
- W2014736621 hasRelatedWork W4230698529 @default.
- W2014736621 hasVolume "18" @default.
- W2014736621 isParatext "false" @default.
- W2014736621 isRetracted "false" @default.
- W2014736621 magId "2014736621" @default.
- W2014736621 workType "article" @default.